Cenicriviroc (INN, code names TAK-652, TBR-652, commonly abbreviated as CVC) is an experimental drug candidate for the treatment of HIV infection and in combination with Tropifexor for non-alcoholic steatohepatitis. It is being developed by Takeda and Tobira Therapeutics.
{{Chembox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 451756573 | ImageFile = Cenicriviroc.svg | ImageClass = skin-invert-image | ImageSize = 315px | ImageAlt = | PIN = (5E)-8-[4-(2-Butoxyethoxy)phenyl]-1-(2-methylpropyl)-N-{4-[(S)-(1-propyl-1H-imidazol-5-yl)methanesulfinyl]phenyl}-1,2,3,4-tetrahydro-1-benzazocine-5-carboxamide | OtherNames = TAK-652; TBR-652
| Section1 =
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).